Drug Therapy

Medication errors in hospitalized children were more common among older age groups, according to research published in The Journal of Pediatrics.

DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve relapsing multiple sclerosis, Gabriel Pardo, MD, said in this Healio video from the American Academy of Neurology annual meeting.

DENVER — Treatment with a novel therapeutic led to clinically significant improvement in cognition for young persons with Angelman syndrome, Kemi Olugemo, MD, FAAN, said in this Healio video at the American Academy of Neurology annual meeting.

DENVER — A combination therapy of ciprofloxacin and celecoxib demonstrated a favorable safety profile for those with amyotrophic lateral sclerosis, Merit Cudkowicz, MD, MSc, said in this Healio video.

The FDA has granted breakthrough therapy designation to a proprietary oligonucleotide conjugate for the treatment of myotonic dystrophy type 1, according to the manufacturer.

DENVER — Losmapimod treatment for those with facioscapulohumeral muscular dystrophy led to no serious adverse events across three clinical trials, according to a poster at the American Academy of Neurology annual meeting.

NEW YORK — One dose of lysergide produced clinical remission of generalized anxiety disorder as soon as 4 weeks after treatment, according to a study presented at the American Psychiatric Association annual meeting.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.

DENVER — For those experiencing chronic migraine, the presence of self-reported psychiatric conditions did not affect the effectiveness of eptinezumab, according to a poster at the American Academy of Neurology annual meeting.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.